These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 11861816)

  • 1. Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo.
    Yamaguchi H; Yano I; Saito H; Inui K
    J Pharmacol Exp Ther; 2002 Mar; 300(3):1063-9. PubMed ID: 11861816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secretory mechanisms of grepafloxacin and levofloxacin in the human intestinal cell line caco-2.
    Yamaguchi H; Yano I; Hashimoto Y; Inui KI
    J Pharmacol Exp Ther; 2000 Oct; 295(1):360-6. PubMed ID: 10992002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of cisplatin-induced acute renal failure on bioavailability and intestinal secretion of quinolone antibacterial drugs in rats.
    Yamaguchi H; Yano I; Saito H; Inui K
    Pharm Res; 2004 Feb; 21(2):330-8. PubMed ID: 15032316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active intestinal secretion of new quinolone antimicrobials and the partial contribution of P-glycoprotein.
    Naruhashi K; Tamai I; Inoue N; Muraoka H; Sai Y; Suzuki N; Tsuji A
    J Pharm Pharmacol; 2001 May; 53(5):699-709. PubMed ID: 11370709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution characteristics of levofloxacin and grepafloxacin in rat kidney.
    Ito T; Yano I; Masuda S; Hashimoto Y; Inui K
    Pharm Res; 1999 Apr; 16(4):534-9. PubMed ID: 10227708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transport characteristics of grepafloxacin and levofloxacin in the human intestinal cell line Caco-2.
    Yamaguchi H; Yano I; Saito H; Inui K
    Eur J Pharmacol; 2001 Nov; 431(3):297-303. PubMed ID: 11730721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limited distribution of new quinolone antibacterial agents into brain caused by multiple efflux transporters at the blood-brain barrier.
    Tamai I; Yamashita J; Kido Y; Ohnari A; Sai Y; Shima Y; Naruhashi K; Koizumi S; Tsuji A
    J Pharmacol Exp Ther; 2000 Oct; 295(1):146-52. PubMed ID: 10991972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cotransport of macrolide and fluoroquinolones, a beneficial interaction reversing P-glycoprotein efflux.
    Sikri V; Pal D; Jain R; Kalyani D; Mitra AK
    Am J Ther; 2004; 11(6):433-42. PubMed ID: 15543082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of multidrug resistance-associated protein 2 in intestinal secretion of grepafloxacin in rats.
    Naruhashi K; Tamai I; Inoue N; Muraoka H; Sai Y; Suzuki N; Tsuji A
    Antimicrob Agents Chemother; 2002 Feb; 46(2):344-9. PubMed ID: 11796340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones.
    Ando T; Kusuhara H; Merino G; Alvarez AI; Schinkel AH; Sugiyama Y
    Drug Metab Dispos; 2007 Oct; 35(10):1873-9. PubMed ID: 17639028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple pathways for fluoroquinolone secretion by human intestinal epithelial (Caco-2) cells.
    Lowes S; Simmons NL
    Br J Pharmacol; 2002 Mar; 135(5):1263-75. PubMed ID: 11877335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible involvement of P-glycoprotein in the biliary excretion of grepafloxacin.
    Zhao YL; Cai SH; Wang L; Kitaichi K; Tatsumi Y; Nadai M; Yoshizumi H; Takagi K; Takagi K; Hasegawa T
    Clin Exp Pharmacol Physiol; 2002 Mar; 29(3):167-72. PubMed ID: 11906478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin.
    Sugie M; Asakura E; Zhao YL; Torita S; Nadai M; Baba K; Kitaichi K; Takagi K; Takagi K; Hasegawa T
    Antimicrob Agents Chemother; 2004 Mar; 48(3):809-14. PubMed ID: 14982769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo investigations on fluoroquinolones; effects of the P-glycoprotein efflux transporter on brain distribution of sparfloxacin.
    de Lange EC; Marchand S; van den Berg D; van der Sandt IC; de Boer AG; Delon A; Bouquet S; Couet W
    Eur J Pharm Sci; 2000 Dec; 12(2):85-93. PubMed ID: 11102735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of P-glycoprotein in determining the oral absorption and clearance of the NK2 antagonist, UK-224,671.
    Beaumont K; Harper A; Smith DA; Bennett J
    Eur J Pharm Sci; 2000 Nov; 12(1):41-50. PubMed ID: 11121732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Site-dependent contributions of P-glycoprotein and CYP3A to cyclosporin A absorption, and effect of dexamethasone in small intestine of mice.
    Jin M; Shimada T; Yokogawa K; Nomura M; Ishizaki J; Piao Y; Kato Y; Tsuji A; Miyamoto K
    Biochem Pharmacol; 2006 Oct; 72(8):1042-50. PubMed ID: 16939683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quercetin significantly decreased cyclosporin oral bioavailability in pigs and rats.
    Hsiu SL; Hou YC; Wang YH; Tsao CW; Su SF; Chao PD
    Life Sci; 2002 Dec; 72(3):227-35. PubMed ID: 12427482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
    Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
    Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males.
    Efthymiopoulos C; Bramer SL; Maroli A
    Clin Pharmacokinet; 1997; 33 Suppl 1():1-8. PubMed ID: 9433650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contributions of intestinal P-glycoprotein and CYP3A to oral bioavailability of cyclosporin A in mice treated with or without dexamethasone.
    Jin M; Shimada T; Yokogawa K; Nomura M; Kato Y; Tsuji A; Miyamoto K
    Int J Pharm; 2006 Feb; 309(1-2):81-6. PubMed ID: 16384676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.